

REFERENCES

1. **Terry es Jardins.** The anatomy and physiology of the circulatory system, In "Cardiopulmonary anatomy and physiology", *Delmar Thomson learning* 2002;5:175-183
 2. **Lawrence M. Boxt and Martin J. Lipton.** Anatomy of the heart and great vessels, In "cardiovascular magnetic resonance imaging", Raymond Y. Kwong , *Human press* 2008;3:79-113
 3. **Sandra Pujadas and Oliver Weber.** Basics of cardiac magnetic resonance and normal views, In "Atlas of practical application of cardiac MR", Guillem Pons-Llado and Francesc Carreras, *Springer* 2005;1:8-28
 4. **Richardson PJ, McKenna W, Bristow M, et al.** Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. *Circulation* 1996; 93:841–842.
 5. **Why H.F, Archard LC, Richardson PJ.** Dilated cardiomyopathy- new insights into the pathogenesis. *Postgrad Med J.* 1994;70:S2-7.
 6. **Elliott P, Andersson B, Arbustini E, et al.** Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J.* Jan 2008;29(2):270-6.
 7. **Stevenson LW, Perloff .K.** The dilated cardiomyopathies: Clinical aspects. *Cardiol Clin.* 1988; 6:187-218.
 8. **Maron BJ, Towbin JA, Thiene G, et al.** Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation.* Apr 11 2006; 113(14):1807-16.
 9. **Goldstein S, Ali AS, Sabbah H.** Ventricular remodeling. Mechanisms and prevention. *Cardiol Clin.* 1998;16(4):623-32, vii-viii.
-

10. **Mark V. Sherid.** Pathophysiology and Treatment of Hypertrophic Cardiomyopathy. *Progress in Cardiovascular Diseases*, 2006; 0: 1-29
 11. **Reisdorff EJ, Prodinge RJ.** Emergency management of cardiac arrhythmias: Sudden cardiac death in the athlete. *Emerg Med Clin North Am.* 1998;16:281-94.
 12. **Maron BJ.** Hypertrophic cardiomyopathy. *Lancet.* 1997;350:127-33.
 13. **Eriksson MJ, Sonnenberg B, Woo A, et al:** Long-term outcome in patients with apical hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002; 39:638- 645.
 14. **Varnava AM, Elliott PM, Mahon N, et al:** Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. *Am J Cardiol* 2001; 88:275- 279,
 15. **Sudhir S. Kushwaha, John T. Fallon and Valentin Fuster.** Restrictive cardiomyopathy. *The new England journal of medicine* 1997; 336(4): 267-276.
 16. **G. Michael Felker, Richard E. Thompson, Joshua M. Hare et al.** Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med.* 2000; 342: 1077-1084.
 17. **Eng CM, Guffon N, Wilcox WR, et al.** Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. *N Engl J Med.* 2001; 345(1): 9-16.
 18. **Rodney H. Falk.** Diagnosis and management of the cardiac amyloidoses. *Circulation.* 2005; 112: 2047-2060.
 19. **Domenico Corrado, Gaetano Thiene,** Arrhythmogenic right ventricular cardiomyopathy/dysplasia: Clinical impact of molecular genetic studies. *Circulation.* 2006; 113: 1634-1637.
 20. **Frances RJ.** Arrhythmogenic right ventricular dysplasia/cardiomyopathy. A review and update. *Int J Cardiol.* Jun 28 2006;110(3):279-87.
-

21. **Pennell DJ, Sechtem UP, Higgins CB, et al.** Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report, *Eur Heart J* 2004;25:1940–1965.
 22. **Leon Axel and Ruth Lim.** Clinical cardiac MRI technique, In "cardiovascular magnetic resonance imaging", Raymond Y. Kwong, *Human press* 2008; 2:33-79.
 23. **Felblinger J, Lehmann C, Boesch C.** Electrocardiogram acquisition during MR examinations for patient monitoring and sequence triggering. *Magn Reson Med* 1994;32:523–529.
 24. **Fischer SE, Wickline SA, Lorenz CH.** Novel real-time R-wave detection algorithm based on the vectorcardiogram for accurate gated magnetic resonance acquisitions. *Magn Reson Med* 1999;42:361–370.
 25. **Boxerman JL, Mosher TJ, McVeigh ER, et al.** Advanced MR imaging techniques for evaluation of the heart and great vessels. *Radiographics* 1998;18:543–564.
 26. **Lenz GW, Haacke EM, White RD.** Retrospective gating: a review of technical aspects and future directions. *Magn Reson Imaging* 1989;7:445–455.
 27. **Sievers B, Addo M, Kirchberg S, et al.** How much are atrial volumes and ejection fractions assessed by cardiac magnetic resonance imaging influenced by the ECG gating method? *J Cardiovasc Magn Reson* 2005;7:587–593.
 28. **Lee VS, Resnick D, Bundy JM, et al.** Cardiac function: MR evaluation in one breath hold with real-time true fast imaging with steady-state precession. *Radiology* 2002;222:835–842.
 29. **J. Paul Finn, Kambiz Nael, Vibhas Deshpande et al.** Cardiac MR imaging: state of technology. *Radiology* 2006; 241 :338-354.
 30. **Sechtem U, Pflugfelder PW, White RD, et al.** Cine MR imaging: potential for the evaluation of cardiovascular function. *AJR Am J Roentgenology* 1987; 148:239-246.
 31. **Pettigrew RI.** Cardiovascular imaging techniques. In: Stark DD, Bradley WB, eds. Magnetic resonance imaging. St Louis: *Mosby-year book*, 1992; 1605-1651.
-

32. **Rebergen SA, van der Wall EE, Doombos J, et al.** Magnetic resonance measurement of velocity and flow: technique, validation, and cardiovascular applications. *Am Heart J* 1993; 126:1439-1456.
33. **Lotz J, Meier C, Leppert A, et al.** Cardiovascular flow measurement with phasecontrast MR imaging: basic facts and implementation. *Radiographics* 2002; 22:651- 671.
34. **Vignaux OB, Augui J, Coste J, et al.** Comparison of single-shot fast spin-echo and conventional spin-echo sequences for MR imaging of the heart: initial experience. *Radiology* 2001;219: 545-550.
35. **Chien D, Edelman RR.** Ultrafast imaging using gradient echoes. *Magn Reson Q* 1991; 7:31-56.
36. **Barkhausen J, Ruehm SG, Goyen M, et al.** MR evaluation of ventricular function: true fast imaging with steady-state precession versus fast low-angle shot cine MR imaging—feasibility study. *Radiology* 2001;219:264–269.
37. **Francois CJ, Fieno DS, Shors SM, et al.** Left ventricular mass: manual and automatic segmentation of true FISP and FLASH cine MR images in dogs and pigs. *Radiology* 2004;230(2):389–395.
38. **Shors SM, Fung CW, Francois CJ, et al.** Accurate quantification of right ventricular mass at MR imaging by using cine true fast imaging with steady-state precession: study in dogs. *Radiology* 2004; 230(2):383–388.
39. **Li W, Storey P, Chen Q, et al.** Dark flow artifacts with steady-state free precession cine MR technique: causes and implications for cardiac MR imaging. *Radiology* 2004;230(2):569– 575.

40. **Wintersperger BJ, Nikolaou K, Dietrich O, et al.** Single breath-hold real-time cine MR imaging: improved temporal resolution using generalized autocalibrating partially parallel acquisition (GRAPPA) algorithm. *Eur Radiol* 2003;13:1931–1936.
 41. **Deimling M, Heid O.** Magnetization prepared TrueFISP imaging [abstract]. In: Proceedings of the First/Second Meeting of the Society of Magnetic Resonance. Berkeley, Calif: Society of Magnetic Resonance, 1994; 495.
 42. **Shankaranarayanan A, Simonetti OP, Laub G, et al.** Segmented k-space and real-time cardiac cine MR imaging with radial trajectories. *Radiology* 2001;221: 827–836
 43. **Fenchel M, Helber U, Simonetti OP, et al.** MultisHce first-pass myocardial perfusion imaging: Comparison of saturation recovery (SR)- TruePISP-two-dimensional (2D) and SR-TurboFLASH- 2D pulse sequences. *J Magn Reson Imaging* 2004; 19:555-563.
 44. **Simonetti OP, Kim RJ, Fieno DS, et al.** An improved MR imaging technique for the visualization of myocardial infarction. *Radiology* 2001; 218:215-223.
 45. **Earls JP, Ho VB, Foo TK, et al.** Cardiac MRI: recent progress and continued challenges. *J Magn Reson Imaging* 2002; 16:111–127.
 46. **Mark W. Hansen , Naeem Merchant .** MRI of hypertrophic cardiomyopathy: part 1, MRI appearances. *AJR* 2007; 189:1335-1343.
 47. **Elena Belloni, Francesco De Cobelli, Antonio Esposito et al:** MRI of Cardiomyopathy. *AJR* 2008; 191: 1702-1710.
 48. **Hassan Abdel-Aty and Matthias G. friedrich.** Magnetic reonance of cardiomyopathies and myocarditis, In "cardiovascular magnetic resonance imaging", Raymond Y. Kwong , Human press 2008;19:399-414.
 49. **Hughes SE.** The pathology of hypertrophic cardiomyopathy. *Histopathology* 2004; 44:412–427.
 50. **Mozaffarian D, Caldwell JH.** Right ventricular involvement in hypertrophic cardiomyopathy: a case report and literature review. *Clin Cardiol* 2001; 24:2–8.
-

51. **Michael Salerno, Christopher M. Kramer.** Prognosis in Hypertrophic Cardiomyopathy With Contrast-Enhanced Cardiac Magnetic Resonance The Future Looks Bright. *J. Am. Coll. Cardiol.* 2010;56:888-889.
 52. **Mandinov L, Eberli FR, Seiler C, Hess OM.** Diastolic heart failure. *Cardiovasc Res* 2000; 45:813–825.
 53. **Basso C, Thiene G, Corrado D, et al.** Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. *Hum Pathol* 2000; 31:988–998.
 54. **Choudhury L, Mahrholdt H, Wagner A, et al.** Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002; 40:2156–2164
 55. **Moon JC, Reed E, Sheppard MN, et al.** The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2004; 43:2260–2264
 56. **Moon JCC, McKenna WJ, McCrohon JA, et al.** Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. *J Am Coll Cardiol* 2003; 41:1561–1567
 57. **Pons-Lladó G, Carreras F, Borrás X, et al.** Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. *Am J Cardiol* 1997; 79:1651–1656.
 58. **Rickers C, Wilke NM, Jerosch-Herold M, et al.** Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. *Circulation* 2005; 112:855–861.
 59. **Sipola P, Lauerma J, Jääskeläinen P, et al.** Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene. *Radiology* 2005; 236:815–824.
 60. **Elliott P, McKenna WJ.** Hypertrophic cardiomyopathy. *Lancet* 2004; 363:1881–1891.
-

61. **Carsten Rickers, Norbert M. Wilke, Michael Jerosch-Herold, et al.** Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy. *Circulation*. 2005;112:855-861
 61. **Maron BJ.** Hypertrophic cardiomyopathy: a systematic review. *JAMA*. 2002;287:1308–1320.
 62. **Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, et al.** American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. *J Am Coll Cardiol*. 2003;42:1687–1713.
 63. **Swingen C, Seethamraju RT, Jerosch-Herold M.** An approach to the three-dimensional display of left ventricular function and viability using MRI. *Int J Cardiovasc Imaging*. 2003;19:325–336.
 64. **Buller VG, van der Geest RJ, Kool MD, et al.** Assessment of regional left ventricular wall parameters from short axis magnetic resonance imaging using a three-dimensional extension to the improved centerline method. *Invest Radiol*. 1997;32: 529–539.
 65. **Wigle ED.** Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy. *Heart* 2001; 86:709–714.
 66. **Kofflard MJ, Ten Cate FJ, van der Lee C, et al.** Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. *J Am Coll Cardiol* 2003; 41:987–993.
 67. **Maron MS, Olivotto I, Betocchi S, et al.** Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med* 2003; 348:295–303.
 68. **Macgowan CK, Kellenberger CJ, Detsky JS, et al.** Real-time Fourier velocity encoding: an in vivo evaluation. *J Magn Reson Imaging* 2005; 21:297–304
-

69. **Tani T, Tanabe K, Ono M, et al.** Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. *J Am Soc Echocardiogr* 2004; 17:644–648.
 70. **Sperling RT, Parker JA, Manning WJ, et al.** Apical hypertrophic cardiomyopathy: clinical, electrocardiographic, scintigraphic, echocardiographic, and magnetic resonance imaging findings of a case. *J Cardiovasc Magn Reson* 2002; 4:291–295.
 71. **Moon JC, Fisher NG, McKenna WJ, et al.** Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. *Heart* 2004; 90:645–649.
 72. **Eriksson MJ, Sonnenberg B, Woo A, et al.** Longterm outcome in patients with apical hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2002; 39:638–645.
 73. **Shirani J, Pick R, Roberts WC, et al.** Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. *J Am Coll Cardiol* 2000; 35:36–44.
 74. **Bergey PD, Axel L.** Focal hypertrophic cardiomyopathy simulating a mass: MR tagging for correct diagnosis. *AJR* 2000; 174:242–244.
 75. **Moon JC, Mogensen J, Elliott PM, et al.** Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. *Heart* 2005; 91:1036–1040.
 76. **Teraoka K, Hirano M, Ookubo H, et al.** Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. *Magn Reson Imaging* 2004; 22:155–161.
 77. **Mahrholdt H, Wagner A, Judd RM, et al.** Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. *Eur Heart J* 2005; 26:1461–1474.
 78. **Amano Y, Kumita S, Takayama M, et al.** Comparison of contrast-enhanced MRI with iodine- 123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. *AJR* 2005; 185:312–318.
-

79. **Amano Y, Takayama M, Takahama K, et al.** Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances. *J Magn Reson Imaging* 2004; 20:595–600.
80. **Bogaert J, Goldstein M, Tannouri F, et al.** Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. *AJR* 2003; 180:981–985.
77. **Mark W. Hansen, Naeem Merchant.** MRI of Hypertrophic cardiomyopathy: Part 2, Differential Diagnosis, Risk Stratification, and Posttreatment MRI Appearances *AJR* 2007; 189:1344–1352.
78. **Fattori R, Rocchi G, Celletti F, et al.** Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. *Am Heart J* 1998; 136:824–830
79. **Maceira AM, Joshi J, Prasad SK, et al.** Cardiovascular magnetic resonance in cardiac amyloidosis. *Circulation* 2005; 111:186–193
80. **Petersen SE, Selvanayagam JB, Francis JM, et al.** Differentiation of athlete's heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2005; 7:551–558.
81. **Pelliccia A, Maron BJ, De Luca R, et al.** Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. *Circulation* 2002; 105:944–949.
82. **Maron BJ.** Sudden death in young athletes. *N Engl J Med* 2003; 49:1064–1075.
86. **Sachdev B, Takenaka T, Teraguchi H, et al.** Prevalence of Anderson- abry disease in male patients with late onset hypertrophic cardiomyopathy. *Circulation* 2002; 105:1407–1411.
87. **Vignaux O.** Cardiac sarcoidosis: spectrum of MRI features. *AJR* 2005; 184:249–254.
88. **Tadamura E, Yamamuro M, Kubo S, et al.** Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. *AJR* 2005; 185:110–115.
-

89. **Dijkmans PA, Visser CA, Kamp O.** An abnormal ECG with inverted T waves in the precordial leads: confirming the diagnosis with contrast enhanced echocardiography. *Heart* 2005; 91:913.
90. **Alter P, Maisch B.** Endomyocardial fibrosis in Churg-Strauss syndrome assessed by cardiac magnetic resonance imaging. *Int J Cardiol* 2006; 108:112–113.
91. **Mann DL, Bristow MR:** Mechanisms and models in heart failure: The biomechanical model and beyond. *Circulation* 2005; 111:2837-2849.
92. **Felker GM, Thompson RE, Hare JM, et al:** Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000; 342:1077-1084.
93. **Thiene G, Corrado D, Basso C:** Cardiomyopathies: is it time for a molecular classification?. *Eur Heart J* 2004; 25:1772-1775.
94. **Ardehali H, Qasim A, Cappola T, et al:** Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. *Am Heart J* 2004; 147:919-923.
95. **Caforio ALP, Mahon NJ, Tona F, et al.** Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. *Eur J Heart Fail* 2002; 4:411–417
96. **Fujimoto S, Nakagawa Y, Mizuno R, et al.** Reduced early diastolic inflow velocities in the antero-posterior transverse direction in the left ventricle of patients with dilated cardiomyopathy. *Int J Card Imaging* 2000; 16:43–48.
97. **Kim RJ, Wu E, Rafael A, et al.** The use of contrastenhanced magnetic resonance imaging to identify reversible myocardial dysfunction. *N Engl J Med* 2000; 343: 1445-1453.

98. **Wu E, Judd RM, Vargas JD, et al.** Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. *Lancet* 2001; 357: 21-28.
 99. **Guillem Pons-llado.** Ventricular morphology and function study of cardiomyopathy, In "Atlas of practical application of cardiac MR", Guillem Pons-Llado and Francesc Carreras, Springer 2005; 2: 29-45.
 100. **McCrohon JA, Moon JC, Prasad SK, et al.** Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. *Circulation* 2003; 108: 54-59.
 101. **Abdel-Aty H, Boye P, Zagrosek A, et al.** Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. *J Am Coll Cardiol* 2005; 45: 1815–1822.
 102. **De Cobelli F, Pieroni M, Esposito A, et al.** Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. *J Am Coll Cardiol* 2006; 47: 1649–1654.
 103. **Hassan Abdel-Aty and Matthias G. Friedrich.** Magnetic Resonance of Cardiomyopathies and Myocarditis, In "cardiovascular magnetic resonance imaging", Raymond Y. Kwong, Human press 2008; 19: 399-414.
 104. **Assomull RG, Prasad SK, Lyne J, et al.** Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. *J Am Coll Cardiol* 2006; 48: 1977–1985.
 105. **Chuang ML, Hibberd MG, Salton CJ, et al.** Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. *J Am Coll Cardiol* 2000; 35: 477-84.
 106. **Bellenger NG, Francis JM, Davies CL, et al.** Establishment and performance of a magnetic resonance cardiac function protocol. *J Cardiovasc Magn Reson* 2000; 2: 15-22.
-

- 107.**Strohm O, Schulz-Menger J, Pik B, et al.** Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy. *J Magn Reson Imaging* 2001; 13: 367-371.
- 108.**Nazarian S, Bluemke DA, Lardo AC, et al.** Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. *Circulation* 2005;112:2821–2825.
- 109.**Oechslin EN, Attenhofer Jost CH, Rojas JR, et al.** Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. *J Am Coll Cardiol* 2000; 36: 493-500.
- 110.**Bax JJ, Atsma DE, Lamb HJ, et al.** Noninvasive and invasive evaluation of noncompaction cardiomyopathy. *J Cardiovasc Magn Reson* 2002; 4: 353-357.
- 111.**Neubauer S.** The failing heart—an engine out of fuel. *N Engl J Med.* 2007;356:1140–1151.
- 112.**Stefan Neubauer.** Metabolic imaging in dilated cardiomyopathy. *Heart Metab.* 2011;49:13–16.
- 113.**Hudsmith LE, Neubauer S.** Magnetic resonance spectroscopy in myocardial disease. *JACC Cardiovasc Imaging.* 2009;2:87– 96.
- 114.**Neubauer, Stefan.** Metabolic imaging with cardiac magnetic resonance spectroscopy. *Heart Metab.* 2009;44:17–20.
- 115.**Neubauer S, Horn M, Pabst T, et al.** Contributions of ³¹P magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. *Eur Heart J.* 1995;16 (Suppl O):115–118.
- 116.**Neubauer S, Horn M, Cramer M, et al.** Myocardial phosphocreatine- to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. *Circulation.* 1997;96:2190–2196.

- 117.**Beer M, Seyfarth T, Sandstede J, et al.** Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured non invasively with P-SLOOP magnetic resonance spectroscopy. *J Am Coll Cardiol.* 2002;40:1267–1274.
 - 118.**Smith CS, Bottomley PA, Schulman SP, et al.** Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. *Circulation* 2006;114:1151–1158.
 - 119.**Nakae I, Mitsunami K, Matsuo S, et al.** Assessment of myocardial creatine concentration in dysfunctional human heart by proton magnetic resonance spectroscopy. *MRM.* 2004;3:19–25.
 - 120.**Walecki J, Michalak MJ, Michalak E, et al.** Usefulness of ¹H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy: pilot study. *Acad Radiol.* 2003;10 (10):1187–1192.
 - 121.**Joshua M. Hare.** The Dilated, Restrictive, and Infiltrative Cardiomyopathies in " Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed", *Saunders* 2007; 64 : 1739- 1763.
 - 122.**Hare JM:** The etiologic basis of congestive heart failure. In: Colucci WS, ed. *Atlas of Heart Failure, Philadelphia: Current Medicine LLC*; 2005:34-58.
 - 123.**Shabetai R.** The Pericardium. *New York: Grune & Stratton*;1981:211.
 - 124.**Harris SR, Glockner J, Misselt AJ, et al.** Cardiac MR imaging of nonischemic cardiomyopathies. *Magn Reson Imaging Clin N Am.* May 2008;16(2):165-83, vii.
 - 125.**Barkhausen J, Hunold P, Eggebrecht H, et al.** Detection and characterization of intracardiac thrombi on MR imaging. *AJR Am J Roentgenol* 2002;179:1539–1544.
 - 126.**Ohyama H, Hosomi N, Takahashi T, et al.** Comparison of magnetic resonance imaging and transesophageal echocardiography in detection of thrombus in the left atrial appendage. *Stroke* 2003;34:2436–2439.
-

- 127.**Jarvinen VM, Kupari MM, Poutanen VP, et al.** A simplified method for the determination of left atrial size and function using cine magnetic resonance imaging. *Magn Reson Imaging* 1996;14: 215–226.
- 128.**Celletti F, Fattori R, NapoU G, et al.** Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging. *Am J Cardiol* 1999; 83: 798-801.
- 129.**Udo Sechtem, Dimiter Tscholakoff, Chatles B. Higgins.** MRI of abnormal pericardium. *AJR* 1986; 147:245-252.
- 130.**Darra T. Murphy, Suzanne C. Shine, Andrea Cradock, et al.** Cardiac MRI in Arrhythmogenic Right Ventricular Cardiomyopathy. *AJR* 2010; 194:W299–W306.
- 131.**Dalal D, Nasir K, Bomma C, et al.** Arrhythmogenic right ventricular dysplasia: a United States experience. *Circulation* 2005; 112:3823–3832.
- 132.**McKenna WJ, Thiene G, Nava A, et al.** Diagnosis of arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. *Br Heart J* 1994; 71:215–218.
- 133.**Tandri H, Saranathan M, Rodriguez ER, et al.** Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. *J Am Coll Cardiol* 2005; 45:98–103.
- 134.**Sen-Chowdhry S, Prasad SK, Syrris P, et al.** Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. *J Am Coll Cardiol* 2006; 48:2132–2140.
- 135.**Nazarian S, Bluemke DA, Lardo AC, et al.** Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. *Circulation* 2005; 112:2821-2825.